New Algorithm Improves Echo-Based Heart Pressure Analysis
A new algorithm for estimating left ventricular filling pressure (LVFP) by echocardiography reduced indeterminate results to just two cases compared with 38 using previous guidelines, achieving 86% accuracy in 949 patients, a new study found. The algorithm showed particular improvement for patients with normal left ventricular ejection fraction (LVEF), while maintaining similar accuracy for cases of reduced LVEF.
METHODOLOGY:
Researchers conducted an observational study involving 951 patients referred for cardiac catheterization across multiple centers in the United States, Norway, South Korea, Spain, and Japan.
The analysis included echocardiographic measurements of mitral inflow; the velocities of the pulmonary vein, tissue Doppler mitral annulus, and tricuspid regurgitation; as well as left atrial strain.
LVFP greater than 15 mm Hg was designated as abnormally elevated.
A secondary evaluation incorporated left atrial reservoir strain, left atrial maximum volume index, isovolumic relaxation time, and pulmonary vein flow when initial variables were discordant or incomplete.
TAKEAWAY:
The new algorithm achieved a sensitivity of 86% and a specificity of 86%, with an overall accuracy of 86% in 949 patients, significantly outperforming joint 2016 guidelines from the American Society of Echocardiography and the European Association of Cardiovascular Imaging (P < .0001).
For patients with normal LVEF, the algorithm demonstrated 85% sensitivity, 87% specificity, and 86% accuracy, showing significant improvement over previous guidelines (P < .0001).
In patients with reduced LVEF, the algorithm had 92% sensitivity, 77% specificity, and 87% accuracy.
The model also was more accurate than the guidelines for patients with an ejection fraction of 50% or greater (P < .0001).
The net reclassification improvement for echocardiography over natriuretic peptides was 1.1 (P < .0001), with integrated discrimination improvement of 0.3 (P < .0001).
IN PRACTICE:
'Application of the new algorithm should result in an increase in the number of patients in whom LV filling pressure can be estimated,' the researchers reported. 'Application of the new algorithm should result in high accuracy in determining LV filling pressure in patients with normal LV ejection fraction. The new algorithm can be combined with natriuretic peptides to correctly identify patients with heart failure.'
SOURCE:
The study was led by Hossam Lababidi, MD, of Methodist DeBakey Heart and Vascular Center in Houston. It was published online in Circulation.
LIMITATIONS:
The study did not examine the role of diastolic stress testing, which is recommended for symptomatic patients with grade 1 diastolic dysfunction. The majority of patients also underwent cardiac catheterization for dyspnea evaluation or heart failure management, suggesting the sample had a higher likelihood of elevated LVFP. The researchers noted that accuracy may be lower when applied to populations with lower prevalence of cardiovascular disease.
DISCLOSURES:
One of the investigators disclosed being a co-inventor of method for myocardial segment work analysis and estimation of blood pressure in the heart and received speaker honorarium from GE HealthCare.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 minutes ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
USA Swimming confirms stomach bug impacting team at worlds
USA Swimming has confirmed reports that some team members competing in the World Aquatics Championships in Singapore were recovering from acute gastroenteritis, US public broadcaster NPR reported. USA Swimming senior communications director Nikki Warner said in a statement cited by NPR that "those experiencing symptoms" were receiving treatment, without saying which swimmers were affected or how they got sick. The team's medical staff was also "advising the team on further preventative and recovery measures," Warner added. The team is "planning to race and perform to the best of our ability for the rest of the meet," Warner said, according to NPR. Acute gastroenteritis, an inflammation of the stomach and intestines, is usually caused by viruses such as Norovirus or bacteria such as On Saturday, Paris 100 metre butterfly gold medallist Torri Huske did not swim the 100m butterfly "to prioritize her efforts in the 4x100m freestyle relay," USA Swimming said. The relay, which had been favoured to win and was anchored by Huske, came second behind Australia on Sunday evening. Claire Weinstein also pulled out of the 400 metre freestyle. Several US swimmers performed below expectations on Sunday and on Monday morning.
